This site is intended for healthcare professionals

FDA approves FoundationOneCDx as companion diagnostic for melanoma.- Foundation Medicine

Read time: 1 mins
Published:9th Dec 2021
Foundation Medicine announced that it has received approval from the FDA for FoundationOneCDx to be used as a companion diagnostic for two groups of current and future FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies targeting BRAFV600E and BRAF/MEK inhibitor combination therapies targeting BRAFV600E or V600K mutations.

This approval makes FoundationOneCDx the only comprehensive genomic profiling (CGP) test approved as a companion diagnostic across two groups of targeted therapies, representing an important step toward simplifying decision making for oncologists.

The first new therapeutics for which FoundationOneCDx is a companion diagnostic under the group approvals are Pfizer’s Braftovi/Mektovi and Novartis Tafinlar (dabrafenib) + Mekinist (trametinib) combination therapeutics. Moving forward FoundationOneCDx will automatically become a companion diagnostic for future BRAF inhibitors that are approved by the FDA under these groups.

Condition: Solid Tumours
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.